Cargando…
Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer
Drug resistance to approved systemic therapies in estrogen receptor–positive (ER+) breast cancer remains common. We hypothesized that factors present in the human tumor microenvironment (TME) drive drug resistance. Screening of a library of recombinant secreted microenvironmental proteins revealed f...
Autores principales: | Shee, Kevin, Yang, Wei, Hinds, John W., Hampsch, Riley A., Varn, Frederick S., Traphagen, Nicole A., Patel, Kishan, Cheng, Chao, Jenkins, Nicole P., Kettenbach, Arminja N., Demidenko, Eugene, Owens, Philip, Faber, Anthony C., Golub, Todd R., Straussman, Ravid, Miller, Todd W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839765/ https://www.ncbi.nlm.nih.gov/pubmed/29436393 http://dx.doi.org/10.1084/jem.20171818 |
Ejemplares similares
-
Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer
por: Hosford, Sarah R., et al.
Publicado: (2019) -
High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer
por: Traphagen, Nicole A., et al.
Publicado: (2021) -
Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer
por: Hampsch, Riley A., et al.
Publicado: (2017) -
Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion
por: Straussman, Ravid, et al.
Publicado: (2012) -
Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer
por: Yang, Wei, et al.
Publicado: (2018)